Retrospective market analysis of medicines for cardiovascular diseases treatment in Ukraine
DOI:
https://doi.org/10.24959/uekj.18.24Keywords:
retrospective analysis, pharmaceutical market, medicine, cardiovascular diseasesAbstract
Diseases of the cardiovascular system (CVS) are becoming more prevalent among people of working age, whose health status significantly affects the country's labor and economic resources. Official WHO statistics state that the mortality of the able-bodied population from various types of diseases of the CVS is increasing every year. More than 75% of deaths from cardiovascular diseases (CVD) occur in countries with medium and low GDP. In Ukraine, almost two-thirds of the population (68%) of the total morbidity rate dies from CVD. Therefore, the ongoing monitoring and analysis of the proposals of medicine presented on the pharmaceutical market (PM) of Ukraine for the treatment of CVD is topical.
Aim. To undertake a retrospective analysis of medicines market recommended for the treatment of CVD in Ukraine.
Results. In retrospective analysis of MD for treatment of CVD in the PM of Ukraine, it was revealed that on average, foreign medicines represented on the market by 7.6 % more than the domestic manufactured medicines. While deviding the medications into domestic and foreign groups for study, it was revealed that during the period 2013-2017 the largest group of foreign medicine offered was the group C09A – ACE inhibitors, the specific gravity was 23.46 % in 2017. The number of domestic medicines offered, it was founded that during 2014-2017 the greatest was the group B01A – antithrombotic agents, the specific gravity in 2017 – 26.71 %, respectively. When analysing the inspected sample according to the drug forms, it was identified a significant prevalence of medicine in the form of tablets – 88.88 %.
Conclusions. In connection with the significant dominance of PM for foreign MD on the territory of Ukraine, the implementation of import substitution programs, as well as the development of reference pricing, in particular the reimbursement of the cost of medicines, to increase the level of access to medicines, is becoming particularly relevant.
References
VOOZ. [World Health Organization]. who.int. Available at: http://www.who.int/ru/ 2. European Society of Cardiology [European Society of Cardiology]. escardio.org. Available at : https://www.escardio.org/ 3. Kotvitskaya, A. A., Krasulya, O. I. (2013). Nauch. Vedomosti Belgorodskogo gos. universiteta, 7 (147), 208–213. 4. Nemchenko, A. S. Kurylenko, Yu. Е. (2017). Zbirnyk naukovykh robit shchorichnoi V mizhnarodnoi naukovo-praktychnoi dystantsiinoi konferentsii «Menedzhment ta marketynh u skladi suchasnoi ekonomiky, nauky, osvity, praktyky». Kharkiv: NUPh, 375. 5. Baygush, Y. V., Slobodyanyuk, M. M. (2016). The study of the assortment and availability beta-adrenoceptor blockers in the retail segment of the domestic pharmaceutical market. Socìal’na Farmacìâ v Ohoronì Zdorov’â, 2 (1), 13–21. https://doi.org/10.24959/sphhcj.16.29 6. Stepanenko, A., Blikhar, V. (2013). Kazakhstansko-Rossiyskogo meditsinskogo universiteta, 3 (3), 60–63. 7. Siatynia, M. L., Popovych, V. P., Nehoda, T. S. (2009). Farmatsevtychnyi chasopys, 2, 61–65. 8. Protokoly zi spetsialnosti «Kardiolohiia». [Protocols on the specialty «Cardiology»]. mtd.dec.gov.ua. Available at: http://mtd.dec.gov.ua/index.php/uk/reiestr-mtd/itemlist/category/17-kardiolohiia 9. Derzhavnyi reiestr likarskykh zasobiv Ukrainy. [State Register of Drugs of Ukraine]. drlz.kiev.ua.Available at: http://www.drlz.kiev.ua/
Downloads
Published
Issue
Section
License
Copyright (c) 2018 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
